JP2006512090A - ボツリヌス神経毒b受容体およびその使用 - Google Patents

ボツリヌス神経毒b受容体およびその使用 Download PDF

Info

Publication number
JP2006512090A
JP2006512090A JP2005507928A JP2005507928A JP2006512090A JP 2006512090 A JP2006512090 A JP 2006512090A JP 2005507928 A JP2005507928 A JP 2005507928A JP 2005507928 A JP2005507928 A JP 2005507928A JP 2006512090 A JP2006512090 A JP 2006512090A
Authority
JP
Japan
Prior art keywords
seq
amino acids
bont
acid sequence
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005507928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512090A5 (cg-RX-API-DMAC7.html
Inventor
エドウィン レイモンド チャップマン
ミン ドン
Original Assignee
ウイスコンシン アラムニ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウイスコンシン アラムニ リサーチ ファンデーション filed Critical ウイスコンシン アラムニ リサーチ ファンデーション
Publication of JP2006512090A publication Critical patent/JP2006512090A/ja
Publication of JP2006512090A5 publication Critical patent/JP2006512090A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2005507928A 2002-10-31 2003-10-28 ボツリヌス神経毒b受容体およびその使用 Pending JP2006512090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42295102P 2002-10-31 2002-10-31
US49812803P 2003-08-27 2003-08-27
PCT/US2003/034348 WO2005016233A2 (en) 2002-10-31 2003-10-28 Botulinum neurotoxin b receptors and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009229744A Division JP2010006833A (ja) 2002-10-31 2009-10-01 ボツリヌス神経毒b受容体およびその使用

Publications (2)

Publication Number Publication Date
JP2006512090A true JP2006512090A (ja) 2006-04-13
JP2006512090A5 JP2006512090A5 (cg-RX-API-DMAC7.html) 2006-06-01

Family

ID=34197667

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005507928A Pending JP2006512090A (ja) 2002-10-31 2003-10-28 ボツリヌス神経毒b受容体およびその使用
JP2009229744A Pending JP2010006833A (ja) 2002-10-31 2009-10-01 ボツリヌス神経毒b受容体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009229744A Pending JP2010006833A (ja) 2002-10-31 2009-10-01 ボツリヌス神経毒b受容体およびその使用

Country Status (10)

Country Link
US (2) US20040191887A1 (cg-RX-API-DMAC7.html)
EP (1) EP1578382B1 (cg-RX-API-DMAC7.html)
JP (2) JP2006512090A (cg-RX-API-DMAC7.html)
AT (1) ATE442161T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003304419A1 (cg-RX-API-DMAC7.html)
CA (1) CA2504532C (cg-RX-API-DMAC7.html)
DE (1) DE60329225D1 (cg-RX-API-DMAC7.html)
ES (1) ES2333319T3 (cg-RX-API-DMAC7.html)
IL (1) IL167943A (cg-RX-API-DMAC7.html)
WO (1) WO2005016233A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023210585A1 (ja) * 2022-04-25 2023-11-02 株式会社Jiksak Bioengineering 標的化剤

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003304419A1 (en) * 2002-10-31 2005-03-07 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
US7341843B2 (en) * 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US8748106B2 (en) * 2005-04-18 2014-06-10 Bal Ram Singh Methods of identifying a compound that increases or decreases the interaction of Hn-33 with synaptotagmin II
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
CN101932936B (zh) 2007-09-14 2016-04-27 拜奥麦迪逊公司 利用切割序列和间隔子的共振能量转移测定
US9303285B2 (en) 2012-01-04 2016-04-05 Biomadison, Inc. Methods and compounds for increasing sensitivity of botulinum assays
US11325954B2 (en) 2011-06-01 2022-05-10 Biomadison, Inc. Compositions and methods for stability testing of botulinum toxin
US12422428B2 (en) 2011-06-01 2025-09-23 Biomadison, Inc. Compositions and methods for cell-based assays
US10908146B2 (en) 2011-06-01 2021-02-02 Biomadison, Inc. Compositions and methods for improving sensitivity in cell based assays
US9274121B2 (en) 2011-06-01 2016-03-01 Biomadison, Inc. Non-FRET botulinum assay
EP3270162B2 (en) 2013-08-09 2023-08-16 BioMadison, Inc. Botulinum toxin assay with improved sensitivity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994995B1 (en) * 2001-03-16 2006-02-07 Lexicon Genetics Incorporated Human synaptotagmin and polynucleotides encoding the same
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
AU2003304419A1 (en) * 2002-10-31 2005-03-07 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
EP2502930B1 (en) * 2003-12-19 2016-06-29 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
WO2008036060A2 (en) * 2005-04-05 2008-03-27 Allergan, Inc. Clostridial toxin activity assays
ES2426194T3 (es) * 2005-08-02 2013-10-21 Planet Biotechnology, Inc. Proteínas quiméricas del receptor de toxina mejoradas y proteínas quiméricas del receptor de toxina para el tratamiento y la prevención de anthrax
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
WO2013011055A1 (en) * 2011-07-19 2013-01-24 ETH Zürich Means and methods for determining clostridial neurotoxins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6008055677, FEBS Lett.,Vol.378(1996)p.253−257 *
JPN6008055678, Neurosci.Lett.,Vol.208(1996)p.105−108 *
JPN6008055748, J.Cell Biol.,Vol.162,No.7(Sept.2003)p.1293−1303 *
JPN6008055749, Microb.Pathog.,Vol.25(1998)p.91−99 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023210585A1 (ja) * 2022-04-25 2023-11-02 株式会社Jiksak Bioengineering 標的化剤

Also Published As

Publication number Publication date
WO2005016233A2 (en) 2005-02-24
AU2003304419A1 (en) 2005-03-07
US20040191887A1 (en) 2004-09-30
EP1578382B1 (en) 2009-09-09
EP1578382A4 (en) 2007-08-29
CA2504532C (en) 2014-09-16
JP2010006833A (ja) 2010-01-14
DE60329225D1 (de) 2009-10-22
US8617573B2 (en) 2013-12-31
WO2005016233A3 (en) 2005-08-18
CA2504532A1 (en) 2005-02-24
AU2003304419A8 (en) 2005-03-07
US20120082672A1 (en) 2012-04-05
ES2333319T3 (es) 2010-02-19
ATE442161T1 (de) 2009-09-15
EP1578382A2 (en) 2005-09-28
IL167943A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
JP2010006833A (ja) ボツリヌス神経毒b受容体およびその使用
Dong et al. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells
US8450277B2 (en) Methods for reducing botulinum neurotoxin A toxicity
Rummel et al. The HCC‐domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction
Rummel et al. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation‐dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor
Wendler et al. Homotypic fusion of immature secretory granules during maturation requires syntaxin 6
Meyer et al. Identification of a gephyrin binding motif on the glycine receptor β subunit
US20080090270A1 (en) Nogo receptor homologues and their use
JP2002510462A (ja) 哺乳類のエンドグルクロニダーゼをコードする単離された核酸分子およびその使用
US8771707B2 (en) Botulinum neurotoxin E receptors and uses thereof
Rickman et al. Comparative analysis of tandem C2 domains from the mammalian synaptotagmin family
US8476024B2 (en) Botulinum neurotoxin a protein receptor and uses thereof
Viswanathan et al. Expression of a functional Drosophila melanogaster CMP-sialic acid synthetase: Differential localization of the Drosophila and human enzymes
JP2004526421A (ja) 真核細胞分裂遺伝子並びに増殖疾患の診断および処置におけるそれらの使用
US20080026363A1 (en) Acetyl coa carboxylase 2 sequences and methods
Wattenberg et al. An artificial mitochondrial tail signal/anchor sequence confirms a requirement for moderate hydrophobicity for targeting
CA2292644A1 (en) Receptor for a bacillus thuringiensis toxin
AU1614400A (en) Human glycine transporter type 2
EP1466975A1 (en) Postsynaptic proteins
Koticha The cysteine-rich domain of SNAP-25 is necessary for plasma membrane targeting and regulated exocytosis
JP2002238578A (ja) ラットedg7受容体
Martín Functional studies of 4F2hc‐CD147 interaction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100423

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100726

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20101029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111111